Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hurthle Cell Carcinoma Workup

  • Author: Serhat Aytug, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
 
Updated: Jun 08, 2016
 

Laboratory Studies

A full set of thyroid function tests should be ordered, including the following:

  • Thyroid-stimulating hormone (TSH)
  • Thyroxine (T4)
  • Triiodothyronine (T3)
  • Free T4

In addition, the following antibody studies should be ordered:

  • Antiperoxidase antibodies
  • Antithyroglobulin antibodies
Next

Imaging Studies

Imaging study findings are as follows:

  • Thyroid uptake and scan: Typical finding is an area of decreased uptake, which corresponds to the tumor
  • Thyroid ultrasound: Ultrasound usually demonstrates a solid mass, as well as characterizes the solid/cystic nature of the lesion, and is also helpful in diagnosing enlarged lymph nodes in the neck
  • MRI of the neck: MRI will provide more detailed information about the tumor and its relation to the other neck structures
  • CT scan of the neck: CT scan provides more detailed information about the tumor and its relation to the other neck structures. CT scan is also helpful for assessment of calcifications
  • Octreotide scintigraphy: This study can be considered for patients with metastatic Hürthle cell carcinoma because evidence suggests that some Hürthle cell neoplasms can express somatostatin receptors.

Positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG PET) has been shown to be helpful in diagnosing metastatic disease in Hürthle cell carcinomas, particularly with tumors that have low iodine avidity. In a study by Pryma et al, 18F-FDG PET was shown to increase diagnostic accuracy over CT and radioactive iodine scan. In addition, in this study, intense 18F-FDG uptake in lesions were an indicator of poor prognosis.[19]

Previous
Next

Fine-Needle Aspiration

Cytologic analysis of fine-needle aspiration (FNA) specimens can diagnose Hürthle cell neoplasm in most patients. However, FNA cannot differentiate Hürthle cell adenoma from Hürthle cell carcinoma, because it does not permit assessment of vascular and capsular invasion, which are the two main factors that differentiate carcinoma from adenoma.

In a study of 139 Hürthle cell lesions, Elliott et al found that the presence of all four of the following cytological features correctly identified Hürthle cell neopla in 86% of cases[20] :

  • Nonmacrofollicular architecture
  • Absence of colloid
  • Absence of inflammation
  • Presence of transgressing blood vessels

MicroRNA expression array has identified novel diagnostic markers in FNA samples for conventional and oncocytic follicular thyroid carcinomas. In this study, novel miR-885-5p was strongly upregulated (>40 fold) in oncocytic follicular carcinomas compared with conventional follicular carcinomas, follicular adenomas, and hyperplastic nodules.[21]

A test that measures the expression of 167 genes may help determine whether a cytologically indeterminate thyroid nodule is benign, and thus may be considered for more conservative treatment. In their study of 265 indeterminate nodules 1 cm or larger, Alexander et al reported that gene-expression classifier testing correctly identified 78 of 85 nodules as suspicious (92% sensitivity; 52% specificity). The negative predictive value of follicular neoplasm or lesion was 94%. Analysis of the aspirates with false-negative results showed that six of the seven had a paucity of thyroid follicular cells, suggesting insufficient sampling of the nodule.[22]   

 In this study, 10 malignant Hurthle cell nodules were present, and 9 were correctly identified as malignant (90%). Twenty one were benign Hurthle-cell adenomas, and 17 of them were correctly identified (81%).[22]

A study by Donatini et al concluded that the cellular proliferation index (Ki67) and GRIM-19, a protein involved in cell proliferation and apoptosis, are potential cytological markers of malignancy in Hürthle cell carcinoma. Compared with adenomas, carcinomas showed elevated Ki67 (p = 0.0004) and reduced expression of GRIM-19 (p = 0.005).[23]     

Nevertheless, until more accurate methods to differentiate benign nodules from malignant ones are available, all patients with the cytologic diagnosis of a Hürthle cell tumor should proceed to surgery to ensure that the carcinomas are identified and managed appropria.  Additionally, as with any other thyroid neoplasm, one must take into account the tumor's size, calcification, echogenicity, and vascularity when considering whether to perform hemithyroidectomy or total thyroidectomy, or to choose observation.

Previous
Next

Histologic Findings

Common histological malignancy criteria, such as architectural distortion, cellular atypia, or pleomorphism, are encountered in both benign and malignant follicular adenomas; these histological criteria are not helpful while evaluating a thyroid mass.

The cytologic features for Hürthle cell neoplasms are hypercellularity, with a predominance of Hürthle cells usually above 75%, few or no lymphocytes, and scanty or absent colloid. Hürthle cells are large and polygonal in shape, with indistinct cell borders. They have a large pleomorphic hyperchromatic nucleus, a prominent nucleolus, and intensely pink fine granular cytoplasm with hematoxylin-eosin staining. See the image below.

A monomorphous cell population of Hürthle cells ar A monomorphous cell population of Hürthle cells arranged in loosely cohesive clusters and single cells. The cells are polyhedral and have abundant granular cytoplasm with well-defined cell borders. The nuclei are enlarged and have a central prominent macronucleolus.

Papillary structures and intranuclear inclusions, features that are not ordinarily associated with Hürthle cell lesions, are occasionally noted. The electron microscopic examination of Hürthle cells in tumor formation is unique, revealing a large cytoplasm that is almost completely filled with mitochondria. This examination also reveals large lysosomelike dense bodies and dilated Golgi zones confined to the apical portion of the cytoplasm. Unusual richness of chromatin is clumped against the inner nuclear membrane and nuclei that are observed as round and dense, with separation of fibrillar and granular substances.

Histopathologic differentiation of Hürthle cell carcinoma from Hürthle cell adenoma is based on vascular and capsular invasion. Capsular invasion refers to tumor cell penetration of the capsule of the neoplasm. Vascular invasion is defined by the presence of tumor penetration of blood vessels within or outside of the capsule of the Hürthle cell lesion. Capsular invasion, vascular invasion, or both diagnose Hürthle cell carcinoma.

Benign diseases (eg, Hashimoto disease, nodular goiter, toxic goiter) usually have no encapsulation. Hürthle cell changes are part of an inflammatory process.

In a study by Volante et al, the role of galectin-3 and HBME-1 (an antimesothelial monoclonal antibody that recognizes an unknown antigen on microvilli of mesothelial cells) tumor markers, as well as the peroxisome proliferator-activated receptor (PPAR) gamma protein expression, were assessed in oncocytic Hürthle cell tumors, including Hürthle cell adenomas, Hürthle cell carcinomas, and an oncocytic variant of papillary carcinoma. In these 152 Hürthle cell tumors (50 Hürthle cell adenomas, 70 Hürthle cell carcinomas, and 32 oncocytic variant of papillary carcinoma), the sensitivity of galectin-3 was 95.1%, the sensitivity of HBME-1 was 53%, and a combination of galectin-3 and HBME-1 was high at 99%. However, the specificity for both markers was 88%, lower than for nononcocytic follicular tumors.[24]

Interestingly, PPAR gamma protein overexpression was absent in all Hürthle cell adenomas tested and present in only 10% of Hürthle cell carcinomas, similar to other reports that confirm the low prevalence of PAX8-PPAR gamma translocations in Hürthle cell carcinomas.

Previous
Next

Staging

Different prognostic criteria and staging systems are used in differentiating thyroid cancer and Hürthle cell cancer. No uniformly accepted staging system and prognostic classification exists for Hürthle cell carcinoma.

The tumor, node, metastases (TNM) system is the most widely used staging system, as depicted in the image below. Most classification systems used in the evaluation of patients with Hürthle cell carcinoma consider such factors as tumor size, patient age, presence of metastases, and major capsular invasion (extensive capsular invasion in multiple sites). The other classification systems used for assessing Hürthle cell carcinoma are conducted with scoring systems, using the generally accepted prognostic factors, such as age, metastasis, extent of disease at operation, and size (AMES) and age, grade, extent, and size (AGES). See the image below.

Tumor, lymph node, metastases (TNM) staging system Tumor, lymph node, metastases (TNM) staging system for papillary and follicular thyroid carcinoma.

See Thyroid Cancer Staging for additional information.

Previous
 
 
Contributor Information and Disclosures
Author

Serhat Aytug, MD Endocrinologist, Division of Endocrinology, Diabetes and Metabolism, St Jude Heritage Medical Group

Serhat Aytug, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Lawrence E Shapiro, MD Chief, Division of Endocrinology and Metabolism, Professor of Medicine, Department of Medicine, Winthrop University Hospital

Lawrence E Shapiro, MD is a member of the following medical societies: American Diabetes Association, American Thyroid Association, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Additional Contributors

Antoni Ribas, MD Assistant Professor of Medicine, Division of Hematology-Oncology, University of California at Los Angeles Medical Center

Disclosure: Nothing to disclose.

References
  1. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. 2004 Mar. 57(3):225-32. [Medline].

  2. Cannon J. The significance of hurthle cells in thyroid disease. Oncologist. 2011. 16 (10):1380-7. [Medline]. [Full Text].

  3. Bronner MP, Clevenger CV, Edmonds PR, Lowell DM, McFarland MM, LiVolsi VA. Flow cytometric analysis of DNA content in Hürthle cell adenomas and carcinomas of the thyroid. Am J Clin Pathol. 1988 Jun. 89(6):764-9. [Medline].

  4. Pisanu A, Sias L, Uccheddu A. Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment. World J Surg. 2004 Aug. 28(8):761-5. [Medline].

  5. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP. Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001 May 15. 19(10):2616-25. [Medline].

  6. Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N. Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol. 2010 Jun 1. 101(7):582-6. [Medline].

  7. Guerrero MA, Suh I, Vriens MR, Shen WT, Gosnell J, Kebebew E, et al. Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma. J Cancer. 2010 Jun 2. 1:23-6. [Medline]. [Full Text].

  8. Maxwell EL, Palme CE, Freeman J. Hürthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg. 2006 Jan. 132(1):54-8. [Medline].

  9. Máximo V, Sobrinho-Simões M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 2000 Aug. 437(2):107-15. [Medline].

  10. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. 2007 Apr. 60(4):377-81. [Medline].

  11. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. 2007 Apr. 60(4):377-81. [Medline].

  12. Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013 May. 98(5):E962-72. [Medline].

  13. American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed: June 3, 2016.

  14. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006 Apr 15. 106(8):1669-76. [Medline].

  15. Cooper DS, Schneyer CR. Follicular and Hürthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am. 1990 Sep. 19(3):577-91. [Medline].

  16. Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. 2004 Dec. 28(12):1266-70. [Medline].

  17. Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016 Feb 26. 16 (1):162. [Medline].

  18. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005 May 23. 92(10):1892-8. [Medline].

  19. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med. 2006 Aug. 47(8):1260-6. [Medline].

  20. Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer. 2006 Apr 25. 108(2):102-9. [Medline].

  21. Jacques C, Guillotin D, Fontaine JF, et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors. J Clin Endocrinol Metab. 2013 May. 98(5):E981-9. [Medline].

  22. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23. 367(8):705-15. [Medline].

  23. Donatini G, Beaulieu A, Castagnet M, Kraimps JL, Levillain P, Fromont G. Thyroid Hürthle cell tumors: research of potential markers of malignancy. J Endocrinol Invest. 2016 Feb. 39 (2):153-8. [Medline].

  24. Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004 Aug. 445(2):183-8. [Medline].

  25. Jillard C, Youngwirth L, Scheri R, Roman S, Sosa JA. Radioactive Iodine Treatment is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma. Thyroid. 2016 May 5. [Medline].

  26. Fernández CA, Puig-Domingo M, Lomeña F, Estorch M, Camacho Martí V, Bittini AL, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009 Mar. 32(3):228-33. [Medline].

  27. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J. 2009 Mar. 56(1):105-12. [Medline].

  28. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hürthle cell carcinoma?. Int J Radiat Oncol Biol Phys. 2003 Jul 15. 56(4):1067-72. [Medline].

  29. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun. 34(3):439-55. [Medline]. [Full Text].

  30. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res. 2005 Jun 1. 65(11):4716-27. [Medline].

  31. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. 2006 Jun 1. 12(11 Pt 1):3425-34. [Medline].

  32. Paphavasit A, Thompson GB, Hay ID, Grant CS, van Heerden JA, Ilstrup DM, et al. Follicular and Hürthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile?. Arch Surg. 1997 Jun. 132(6):674-8; discussion 678-80. [Medline].

  33. Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009 Mar. 35(3):230-4. [Medline].

  34. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013 Feb 1. 119(3):504-11. [Medline].

  35. Arganini M, Behar R, Wu TC, Straus F 2nd, McCormick M, DeGroot LJ, et al. Hürthle cell tumors: a twenty-five-year experience. Surgery. 1986 Dec. 100(6):1108-15. [Medline].

  36. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hürthle cell carcinoma. Surgery. 1995 Oct. 118(4):711-4; discussion 714-5. [Medline].

  37. Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?. Ann Surg. 1998 Apr. 227(4):542-6. [Medline].

  38. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab. 2000 Feb. 85(2):878-82. [Medline].

  39. Devita VT, Hellman S, Rosenberg SA. Cancer of the Endocrine System. Cancer: Principles and Practice of Oncology. 7th Ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004.

  40. Fagin JA. Molecular genetics of tumors of thyroid follicular cells. Werner & Ingbar's The Thyroid. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 2000. 886-94.

  41. Gosain AK, Clark OH. Hürthle cell neoplasms. Malignant potential. Arch Surg. 1984 May. 119(5):515-9. [Medline].

  42. Grant CS. Operative and postoperative management of the patient with follicular and Hürthle cell carcinoma. Do they differ?. Surg Clin North Am. 1995 Jun. 75(3):395-403. [Medline].

  43. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998 Nov. 39(11):1903-6. [Medline].

  44. Larsen PR, Davies TF, Hay IA. Molecular Pathogenesis (Follicular carcinoma). Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders, Co; 1998. 490-3.

  45. Luna-Ortiz K, Hurtado-Lopez LM, Valderrama-Landaeta JL, Ruiz-Vega A. Thyroglossal duct cyst with papillary carcinoma: what must be done?. Thyroid. 2004 May. 14(5):363-6. [Medline].

  46. Mazzaferri EL. Thyroid cancer in thyroglossal duct remnants: a diagnostic and therapeutic dilemma. Thyroid. 2004 May. 14(5):335-6. [Medline].

  47. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. 1996 Dec. 120(6):1000-4; discussion 1004-5. [Medline].

  48. McHenry CR, Sandoval BA. Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am. 1998 Oct. 7(4):893-910. [Medline].

  49. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol. 1996 Jun. 20(6):686-94. [Medline].

  50. Ron E, Schneider AB. Thyroid Cancer. Schottenfeld, D Fraumeni J eds. Cancer. Epidemiology and Prevention. 3rd ed. Oxford University Press: 2006.

  51. Rosen IB, Luk S, Katz I. Hürthle cell tumor behavior: dilemma and resolution. Surgery. 1985 Oct. 98(4):777-83. [Medline].

  52. Sanders LE, Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery. 1998 Dec. 124(6):967-74. [Medline].

  53. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998 Jan 29. 338(5):297-306. [Medline].

  54. Tallini G. Oncocytic tumours. Virchows Arch. 1998 Jul. 433(1):5-12. [Medline].

  55. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc. 1984 Dec. 59(12):851-5. [Medline].

 
Previous
Next
 
Tumor, lymph node, metastases (TNM) staging system for papillary and follicular thyroid carcinoma.
A monomorphous cell population of Hürthle cells arranged in loosely cohesive clusters and single cells. The cells are polyhedral and have abundant granular cytoplasm with well-defined cell borders. The nuclei are enlarged and have a central prominent macronucleolus.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.